BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nova Pneuma Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Nova Pneuma Inc.'s drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05077904-8884@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270329
DTEND;VALUE=DATE:20270330
SUMMARY:Staccato Alprazolam: Phase 3 readout est. (NCT05077904)
DESCRIPTION:Staccato Alprazolam\, phase 3\, Epilepsy.\nStudy: A Study to Te
 st the Efficacy and Safety of Staccato Alprazolam in Study Participants 12
  Years of Age and Older With Stereotypical Prolonged Seizures\nEstimated p
 rimary completion: 29 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/staccato-alprazolam#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05077904
URL:https://assetmemo.bio/drug/staccato-alprazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076617-8884@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Staccato Alprazolam: Phase 3 readout est. (NCT05076617)
DESCRIPTION:Staccato Alprazolam\, phase 3\, Epilepsy.\nStudy: A Study to Te
 st the Safety and Tolerability of Staccato Alprazolam in Study Participant
 s 12 Years of Age and Older With Stereotypical Prolonged Seizures\nEstimat
 ed primary completion: 30 November 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/staccato-alprazolam#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05076617
URL:https://assetmemo.bio/drug/staccato-alprazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
